Developing novel small molecules to address the underlying cause of genetic diseases.

Reported to CTO. Functional responsibility for large segment of Corteva's R&D organization, focused on laboratory and greenhouse operations. As side project led establishment of CLIA-certified Covid testing lab that developed one of first commercial saliva-based tests and went on to develop an ultra-high throughput low-cost endpoint PCR test using the Nexar system

Leader of 450 person R&D group with 6 global locations responsible for transgenic product development and genomics. Built world class competencies in NGS (including novel applications of Illumina, PacBio, and Bionano), plant transformation, genome editing (including discovery and development of a novel Cas system), molecular analysis, and plant phenotyping.

Co-founder of bacteriotherapy company focused on C. difficile

Leader in McKinsey's pharmaceutical practice with therapeutic focus on oncology and functional focus on R&D operations (Fall 1999 -Spring 2006 and Fall 2008 to Spring 2010)

Designed and built specialty anti-infective sales force including physician targeting, training, and operations